University Hospitals Seidman Cancer Center researchers have developed a tool that could identify metastatic prostate cancer ...

Decision making is evidence based and must be shielded from lobbying The NHS draft recommendation against routine prostate ...

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have launched a clinical trial, called ANDROMEDA, to ...

Recent advances in cancer biology have revealed that refractory malignancies, such as castration-resistant prostate cancer, pancreatic ductal ...

GG1 prostate cancer can have heterogeneous outcomes, with some patients having intermediate- or high-risk disease, challenging the notion of GG1 as uniformly low-risk. Removing the cancer label for ...

In a previous study, the researchers showed that PSA scores can impact both doctor and patient behavior, leading to biopsy ...

Prostate cancer patients with metastatic disease and low-volume primary tumors appear to have a poor prognosis, according to ...

Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy. When blocked, these enzymes cause the androgen receptor to collapse, ...

Higher BMI statuses were associated with improved survival among patients with prostate cancer, especially those with metastatic disease. Overweight and obesity are associated with improved overall ...